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Abstract: The last several decades have witnessed a substantial decrease in the incidence of 
acute allograft rejection following kidney transplantation, although commensurate improve-
ments in long-term graft function have not been realized. As a result, the primary focus of 
new immunosuppressive drug development has expanded to include ease of use and improved 
side effect profile, including reduced nephrotoxicity, in addition to the more traditional goal 
of improved short-term outcomes. A number of novel drugs are currently under investigation 
in Phase I, II, or III clinical trials, primarily to replace the nephrotoxic but highly effective 
calcineurin inhibitors. Belatacept is a humanized antibody that inhibits T cell costimulation 
and has shown encouraging results in multiple Phase II and III trials. This article reviews the 
mechanism of action of belatacept, as well as published and preliminary results of the Phase I–III 
clinical trials involving this novel immunosuppressive agent.
Keywords: kidney transplantation, T cell costimulation, immunosuppression, graft rejection, 
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Introduction
Kidney transplantation is the treatment of choice for end-stage renal disease.1 A total 
of 292,427 kidney transplants were performed in the US by the end of 2009.2 The 
use of better donor–recipient selection algorithms, novel surgical techniques, and 
improved post-transplant care have all led to a significant improvement in short-term 
graft survival, which currently approaches 90% in the first year after transplant.3 
However, the most significant impact in this improvement is the introduction of more 
potent immunosuppressive therapy. The goal of immunosuppressive therapy in renal 
transplantation is to minimize acute and chronic rejection while, at the same time, 
balancing these beneficial effects with their adverse effects, which include the devel-
opment of increased cardiovascular risk factors, infections, and malignancies. Current 
immunosuppression strategies are primarily based on an induction regimen using 
a monoclonal or polyclonal antibody, followed by “maintenance immunosuppression” 
consisting of calcineurin inhibitors (cyclosporine or tacrolimus), an antiproliferative 
agent (mycophenolate mofetil), and low-dose corticosteroids (prednisone).4
Unfortunately, improvement in short-term graft survival has not been reflected 
in improved long-term outcomes.5 Five-year graft survival continues to lag behind 
and is currently estimated to be approximately 72%.6 The primary causes of late 
allograft loss include chronic allograft dysfunction and death with a functioning 
graft.7 Chronic allograft dysfunction can result from multiple causes, including 
chronic immune-  mediated injury, interstitial fibrosis, and tubular atrophy, as well as Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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the chronic toxic effect of calcineurin inhibitors.8 Histologic 
data from   protocol renal allograft biopsies demonstrated the 
presence of calcineurin inhibitor-induced nephrotoxicity in 
50% of renal transplant recipients at two years and 100% at 
10 years after transplant.8 Long-term mortality in the adult 
renal transplant recipient is also estimated to be nearly four 
times that of the general population.9 A large proportion of 
this decreased patient survival is secondary to an increased 
burden of cardiovascular disease and infections in renal trans-
plant recipients.10 Calcineurin inhibitors have been associated 
with the development and worsening of hypertension and 
hyperlipidemia, as well as diabetes.11
Various calcineurin inhibitor minimization and with-
drawal strategies have been attempted, with mixed results.12,13 
The use of mTOR (mammalian target of rapamycin) inhibi-
tors (sirolimus and everolimus) for calcineurin inhibitor 
minimization/withdrawal has been hampered by an adverse 
side effect profile.14 Therefore, calcineurin inhibitors cur-
rently remain the cornerstone of maintenance immunosup-
pression in renal transplant recipients. By the end of 2007, 
close to 99% of renal transplant recipients were discharged 
on calcineurin inhibitors.15 The current trend in drug develop-
ment is focused on preservation of long-term function and 
minimization of the adverse reactions of immunosuppressive 
drugs. Multiple small molecules and biologic agents are 
currently being studied.16,17 T cell costimulation blockade is 
a promising approach and is being intensively investigated 
since the development of belatacept. In this review we discuss 
the mechanism of action, preclinical and clinical data, and 
the side effect profile of belatacept.
Mechanism of alloimmune 
recognition
The ability of T cells to recognize nonself antigens is critical 
for an effective immune response.18 Antigen-presenting cells 
(dendritic cells, macrophages, and B cells) are specialized 
cells capable of activating T cells. To trigger an adequate 
alloimmune response, a series of pathways must be activated. 
All immunosuppressive agents in use today interfere with spe-
cific steps of these pathways. First, nonself or alloantigens are 
displayed by major histocompatibility complex (MHC) mole-
cules on the surface of antigen-presenting cells (see   Figure 1). 
“Signal 1” is transmitted when the MHC –   allopeptide com-
plex engages a specific T cell receptor, leading to initiation of 
the signaling process from the CD3 complex. This interaction 
leads to activation of several signal transduction pathways, 
including the calcium – calcineurin pathway, which activates 
the nuclear factor of activated T cell.
To amplify the T cell response further, “Signal 2” or 
“costimulation” must be transmitted (see Figure 1). This 
signal is mediated by the interaction of CD80 (B7.1) 
and CD86 (B7.2) on antigen-presenting cells with spe-
cific T cell receptors (CD28 and its homolog, cytotoxic 
T lymphocyte-associated antigen 4 [CTLA4]). CD28, a 
disulfide-linked homodimeric transmembrane member of 
the   immunoglobulin superfamily, is constitutively expressed 
on all naïve CD4 and CD8 T cells, although some mature T 
cells, especially memory CD8 T cells, are CD28-negative.19 
In contrast with CD28, CTLA4 delivers signals that   attenuate 
T cell proliferation. Ligation of CD28 by CD80/86 is 
required for clonal expansion of naïve CD4 T cells. Once 
activated, T cells express increased concentration of CTLA4. 
Because CTLA4 has a higher affinity than CD28 for the 
CD80/86 ligand, it binds to most of the available molecules, 
effectively shutting down further T cell   proliferation. Thus, 
costimulatory molecules can provide positive or   negative 
signals to T cells. For complete T cell activation and 
  differentiation, costimulation is essential. In the absence of 
a “signal”, T cells will either undergo apoptosis or develop 
donor-specific anergy.20 Activation of Signals 1 and 2 leads 
to expression of cytokines, especially interleukin-2. These 
cytokines activate the mTOR via the janus kinase 3 and 
phosphoinositide-3 kinase signal transduction pathways, 
leading to further propagation of the lymphocyte cell cycle. 
This last step is termed “Signal 3”.
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Figure 1 T cell costimulation and mechanism of action for belatacept. “Signal 1” 
is delivered through the T cell receptor after presentation of alloantigen bound 
to MHC molecules on APCs. “Signal 2” or costimulation is initiated through the 
binding of CD80 and CD86 on APCs to CD28 and its homolog, CTLA4, on T cells. 
Belatacept, developed through fusion of CTLA4 with the Fc constant region of 
human  immunoglobulin  (Fcγ),  blocks  APC  stimulation  of  T  cell  CD28,  thereby 
inhibiting the immune response.
Abbreviations: APC, antigen-presenting cells; CTLA4, cytotoxic T lymphocyte-
associated antigen 4; MHC, major histocompatibility complex.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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Mechanism of action
Molecules that prevent T cell costimulation have emerged as 
promising immunomodulatory agents. CTLA4-Ig   (abatacept) 
was the first molecule to be developed by fusion of the extra-
cellular domain of CTLA4 with the constant region   fragment 
(Fcγ) of human IgG1 to increase its serum   half-life.21 Given 
the higher affinity of CTLA4 for CD80/86, CTLA4-Ig should 
theoretically block antigen-presenting cell stimulation of 
T cells through CD28, thereby terminating the immune 
response (see Figure 1). However, the Fcγ region can inde-
pendently bind to multiple receptors that modulate immune 
responses, including antibody-dependent cellular cytotoxic-
ity and complement-dependent cytotoxicity. Thus, in abata-
cept, a series of directed cysteine to serine mutations were 
introduced in the hinge region to reduce this   Fc-mediated 
binding.21 Although abatacept proved to be highly efficacious 
for autoimmune T cell-mediated autoimmune disorders, 
such as rheumatoid arthritis and psoriasis, it was found to 
be an inadequate maintenance immunosuppressive agent in 
nonhuman primate models of transplantation.22–24 Studies 
into potential reasons for this disconnect found that although 
CTLA4 binds with a much higher avidity to CD80 and CD86 
than does CD28, CTLA4-Ig was significantly less potent at 
inhibiting CD86-dependent as opposed to CD80-dependent 
costimulation.25
Thus, it was reasoned that a CTLA4-Ig protein with a 
higher avidity for CD86 could be developed. Using a rational 
mutagenesis and screening strategy, a daughter molecule, 
LEA29Y (belatacept, Bristol-Myers Squibb, New York, NY, 
USA), with two amino acid substitutions (L104-.E and 
A29-.Y), was developed.26 Belatacept was found to bind 
four times more avidly to CD86 and two times more avidly 
to CD80 than the parent compound, abatacept. This improved 
binding results in an approximately 10-fold more potent inhi-
bition of T cell activation.26 Flow cytometric studies in renal 
transplant patients have demonstrated that belatacept saturates 
both CD80 and CD86 receptors in whole blood and dendritic 
cell cultures, although the belatacept concentrations required 
for CD86 receptor saturation were approximately 10-fold 
higher than those required for CD80 saturation.27 In a study 
published only in abstract form, Davis et al reported that, like 
abatacept, belatacept did not mediate antibody-  dependent 
cellular cytotoxicity or complement-dependent cytotoxic-
ity of target B cells through its Fc domain. These findings 
suggest that the immunomodulatory activity is mediated 
  predominantly through inhibition of CD28 signaling.28
In humans, CD4+ CD25+ regulatory T cells (Tregs) con-
stitute 5%–15% of peripheral CD4+ T cells, and are   surmised 
to have an important suppressive role in the pathologic 
immune responses after transplantation.29 The fork head tran-
scription factor, FOXP3, is essential for the development of 
Tregs. Interleukin-2 and CD28 costimulation has been shown 
to be an essential survival factor for Tregs.30 Thus, drugs that 
target these pathways could have a potentially deleterious 
effect on Treg survival.31   Reassuringly, data from a Phase II 
belatacept renal transplant study showed that costimulation 
blockade did not interfere with Treg homeostasis. The authors 
presented several hypotheses as to why Treg homeostasis 
was not altered by belatacept, including the possibility that 
human Tregs might not be as sensitive to CD28 costimula-
tion blockade as mouse Tregs; that allotransplantation could 
result in the development of CD28-independent adaptive 
Tregs; that other costimulatory molecules, like CD2, could 
function as a substitute for the CD28 pathway; and, finally, 
that long-term intermittent dosing of belatacept could have 
a subsaturating effect on CD86, allowing Tregs to receive 
sufficient CD28 signaling in order to maintain their survival. 
A significant increase in intragraft FOXP3+ T cells was also 
noted in belatacept-treated patients. The authors surmised 
that this may lead to better resolution of graft rejection epi-
sodes and potentially promote tolerance.32 The number of 
patients was too small, however, to evaluate the impact of 
this finding on overall graft survival.
Maintenance immunosuppressant  
in renal transplantation
Preclinical trials
Various in vitro and in vivo studies have examined the effi-
cacy of combined CD80/86 blockade. Vierboom et al showed 
that a combination of anti-CD80 and anti-CD86 monoclonal 
antibodies resulted in a complete abrogation of the primary 
alloimmune response among peripheral mononuclear blood 
cells obtained from Rhesus monkeys.33 In an animal model, 
Kirk et al demonstrated that administration of anti-CD80 
and anti-CD86 monoclonal antibodies resulted in a delayed 
onset of acute allograft rejection without global T cell or 
B cell depletion. However, although treatment with mono-
clonal antibodies alone (without other immunosuppressive 
drugs) was sufficient to maintain graft survival, rejection 
occurred as soon as the treatment ceased, suggesting that 
the therapy was not tolerogenic.34 Montgomery et al showed 
a greater rejection-free survival rate but a lack of durable 
tolerance with combination anti-CD80, anti-CD86, and 
anti-CD154 monoclonal antibodies.35 In a study on human 
and pig peripheral mononuclear blood cells, Emamaullee 
et al showed that both belatacept and basiliximab, either as Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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monotherapy or as combination therapy, potently inhibited 
allogeneic immune responses.36
Table 1 lists the results of various animal studies examin-
ing the use of belatacept in solid organ transplantation. In 
a nonhuman primate model, Larsen et al’s landmark study 
demonstrated that belatacept monotherapy was inferior 
to combination therapy with belatacept and conventional 
immunosuppressive drugs in preventing allograft rejection.26 
Importantly, belatacept did prevent development of donor-
specific antibodies, which is a major contributor to chronic 
allograft loss in clinical settings.37
Clinical trials
Table 2 lists the ongoing and completed clinical trials investi-
gating the use of belatacept in renal transplantation. The first 
clinical trial on the use of belatacept in renal transplantation 
was a Phase II noninferiority trial comparing the efficacy of 
belatacept with cyclosporine for prevention of acute rejection 
at six months post-transplant.38 In a partially blinded, parallel 
group, multicenter study, the Belatacept Study Group random-
ized 218 renal transplant recipients to receive a more intensive 
(11 infusions of 10 mg/kg over the first six months, followed 
by 5 mg/kg every 4–8 weeks) or less intensive (five infusions 
of 10 mg/kg over the first three months, followed by 5 mg/kg 
every 4–8 weeks) belatacept regimen or cyclosporine. Belata-
cept was administered as a 30-minute intravenous infusion. 
All patients also received mycophenolate mofetil and corti-
costeroids as maintenance immunosuppression and induction 
with basiliximab. At six months, the incidence of acute rejec-
tion was similar in all three groups, being 7%, 6%, and 8% in 
the more intensive belatacept, less intensive belatacept, and 
cyclosporine groups, respectively. The grades of acute rejec-
tion were also similar, although the less intensive belatacept 
group experienced a higher incidence of subclinical rejection 
and treated episodes of subclinical rejection (20% and 15%) 
compared with the more intensive belatacept (9% and 8%) 
and cyclosporine (11% and 7%) groups. Most importantly, 
glomerular filtration rate, as measured by iohexol clearance, 
was significantly higher in the belatacept groups compared 
with the cyclosporine arm. Consistent with this finding, 
protocol biopsies demonstrated a 15%–24% reduction in the 
incidence of chronic allograft nephropathy in the belatacept 
groups. The belatacept groups had a statistically significant 
lower risk of developing diabetes and need for treatment of 
hyperlipidemia, and a lower incidence of hypertension.
In a recently presented Phase II study, 89 Epstein–Barr 
virus (EBV) seropositive adult renal transplant recipients 
were randomized 1:1:1 to receive belatacept + mycophenolate 
mofetil (n = 33), belatacept + sirolimus (n = 26), or tacrolimus 
+ mycophenolate mofetil (n = 30). All patients received thymo-
globulin induction. Although the overall glomerular filtration 
rate was better in the belatacept-treated groups, acute rejection 
rates were higher in the belatacept + mycophenolate mofetil 
arm. At the end of 12 months, 2/33 patients in the belatacept + 
mycophenolate mofetil group and 2/26 patients in the belatacept 
+ sirolimus group had lost their allograft compared with none 
in the tacrolimus + mycophenolate mofetil group. The authors 
concluded that use of belatacept in renal transplant recipients 
may enable calcineurin inhibitor and corticosteroid avoidance, 
with acceptable rates of acute rejection and improved glomeru-
lar filtration rate, although graft loss remains a concern.39
BENEFIT (Belatacept Evaluation of Nephroprotection 
and Efficacy as First line Immunosuppression Trial) is a 
  three-year, Phase III clinical trial that randomized patients 
to three groups, ie, cyclosporine (n = 231), less intensive 
belatacept (n = 231), and more intensive belatacept (n = 225). 
Patients received induction with basiliximab and were main-
tained on mycophenolate mofetil and corticosteroids. Based 
Table 1 Animal studies of belatacept in solid organ transplantation
Animal model Transplant organ Drug combination Median survival
Rhesus monkey26 Renal allograft Abatacept monotherapy
Belatacept monotherapy
Belatacept/MMF/steroids
Basiliximab induction; 
belatacept
8 days
35 days
155 days
.100 days
Rhesus monkey51 Islet allograft Anti-CD40 monotherapy
Belatacept monotherapy
Belatacept/anti-CD40
16 days
59 days
220 days
Rhesus monkey52 Neonatal islet 
xenograft
Basiliximab + anti-CD154 
induction; belatacept + sirolimus
.140 days
Rhesus monkey53 Adult islet 
xenograft
Basiliximab + anti-CD154 induction; 
belatacept + sirolimus
2/5 (20%) 
engraftment
Abbreviation: MMF, mycophenolate mofetil.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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upon the results published so far, patient and graft survival are 
similar across the three groups at both one year (96% more 
intensive belatacept; 96% less intensive belatacept; and 93% 
cyclosporine) and two years (94% more intensive belatacept; 
95% less intensive belatacept; and 91% cyclosporine) post-
transplant.40,41 At the end of one year, although the incidence 
of acute rejection was greater for more intensive (22%) and 
less intensive (17%) belatacept compared with cyclosporine 
(7%), no apparent impact on graft survival was demonstrated. 
Most acute rejection episodes occurred within the first three 
months. Banff $ IIB acute rejection occurred more frequently 
in belatacept-treated (less intensive 5%; more intensive 
10%) compared with cyclosporine-treated patients (1%). 
At the end of two years, glomerular filtration rate continued 
to be significantly higher (15–17 mL/min) in the belatacept-
treated patients. Belatacept-treated patients also had sustained 
  benefits in their cardiovascular and metabolic risk profile.
BENEFIT-EXT (Belatacept Evaluation of Nephropro-
tection and Efficacy as First-line Immunosuppression Trial-
EXTended criteria donors) is a three-year, randomized Phase 
III study in renal transplant recipients receiving an extended 
criteria donor kidney allograft (n = 543).42 The rationale for 
this trial was that because extended criteria donor recipients 
have a heightened risk of allograft loss, they might derive a 
significant benefit from the non-nephrotoxic belatacept. At 
the end of the first year, patient and graft survival was similar 
across the three groups. Renal function was statistically supe-
rior for more intensive belatacept versus cyclosporine (52 mL/
min more intensive belatacept; 45 mL/min cyclosporine) 
but not for less intensive belatacept (50 mL/min) versus 
cyclosporine. Surprisingly, the incidence of chronic allograft 
nephropathy was similar (45% more intensive belatacept; 
46% less intensive belatacept; 52% cyclosporine) across the 
three groups. The recently reported two-year results echo 
the findings of the first year of the study, although only 64% 
of the originally enrolled subjects completed the study.43 In 
the abstract, the authors conclude that the more intensive 
belatacept regimen does not confer any additional efficacy 
over the less intensive regimen. Based upon current data, it 
seems likely that BENEFIT-EXT might not meet its primary 
endpoint of better graft survival with belatacept therapy at the 
end of the three-year study period. Encouragingly, though, 
diabetes and cardiovascular risk   factors were lower in the 
belatacept-treated patients.
Based upon an interim report, another Phase II study is 
being conducted in stable renal transplant recipients main-
tained on calcineurin inhibitor-based regimens. Patients 
6–36 months post-transplantation (n = 173) with glomerular 
filtration rates of 35–75 mL/min were randomized to either 
belatacept 5 mg/kg (less intensive) or continued treatment 
with a calcineurin inhibitor. Seven percent of the belatacept-
treated patients had acute rejection compared with none 
in the calcineurin inhibitor group. Although patient and 
graft survival remained similar in both groups, glomerular 
  filtration rate improved significantly in the belatacept group 
at the end of 12 months.44
A systematic review of randomized controlled trials was 
recently presented at the 2010 International Congress of  The 
Table 2 Clinical trials of belatacept in renal transplantation
Trial Treatment groups Acute 
rejection
Graft loss GFR at end 
of study (mL/min)
Notes
Phase II, 6-month, 
randomized, partially 
blinded, parallel 
group38
Mi belatacept
Li belatacept
CsA
5/74 (7%)
4/71 (6%)
6/73 (8%)
3/74 (4%)
1/71 (1%)
2/73 (3%)
66*
62**
54
Basiliximab induction with MMF + 
steroids as maintenance 
Phase ii, 1-year, 
randomized, open- 
label39
Belatacept + MMF
Belatacept + sirolimus
tacrolimus + MMF
5/33 (15%)
1/26 (4%)
1/30 (3%)
2/33 (6%)
2/26 (8%)
0/30 (0%)
64
62
54
Thymoglobulin induction.  
P values not reported
Phase iii, 
randomized, partially  
blinded, multicenter  
(BENEFIT)40
Mi belatacept
Li belatacept
CsA
49/219 (22%)
39/226 (17%)
16/221 (7%)
4/219 (2%)
5/226 (2%)
8/221 (4%)
65§
63§
50
One year results. Basiliximab 
induction with MMF + steroids as 
maintenance
Phase iii, 
randomized, partially  
blinded, multicenter  
(BENEFIT-EXT)42
Mi belatacept
Li belatacept
CsA
33/184 (18%)
31/175 (18%)
26/184 (14%)
17/184 (9%)
16/175 (9%)
20/184 (11%)
52†
49††
45
One-year results. Basiliximab 
induction with MMF + steroids as 
maintenance 
Abbreviations: GFR, estimated glomerular filtration rate; MI, more intensive; MMF, mycophenolate mofetil; CsA, cyclosporine A; LI, less intensive; BENEFIT, Belatacept 
Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial; BENEFIT-EXT, Belatacept Evaluation of Nephroprotection and Efficacy as First-line 
Immunosuppression Trial-EXTended criteria donors.
Notes: *P = 0.01; **P = 0.04 versus standard CsA; §P < 0.01 versus standard CsA; †P < 0.01; ††P = 0.1 versus standard CsA.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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Transplantation Society meeting.45 Based upon the report, 
patients treated with belatacept had a 69% lower chance 
of dying compared with those treated with tacrolimus. The 
odds ratios (ORs) of graft loss with belatacept were not sta-
tistically different relative to cyclosporine (OR = 0.70, 95% 
credible interval 0.32–1.50) or tacrolimus (OR = 0.82, cred-
ible interval 0.35–1.84), although acute rejection odds were 
significantly higher (OR = 2.61, credible interval 1.29–4.91) 
relative to tacrolimus. The odds of development of new-
onset diabetes after transplantation were significantly lower 
(OR = 0.19, credible interval 0.08–0.42) with belatacept 
compared with both calcineurin inhibitors.
Multiple other trials, including the use of belatacept along 
with various agents like sirolimus and alemtuzumab, are cur-
rently in progress.46 Because tacrolimus has largely replaced 
cyclosporine as the calcineurin inhibitor of choice, trials 
comparing tacrolimus with belatacept would be crucial in 
confirming the results presented above. Ashman et al reported 
successful use of belatacept as maintenance immunosuppres-
sion in a young kidney transplant patient who developed de 
novo thrombotic microangiopathy serially in association with 
cyclosporine, tacrolimus, and sirolimus.47 A compassionate 
use study to make belatacept available for renal transplant 
recipients who are intolerant to or having contraindications 
to calcineurin inhibitors and/or mTOR inhibitors is currently 
enrolling patients.
Adverse reactions
In human studies, belatacept appears to have predictable 
pharmacokinetics. No definitive relationship, however, has 
been established between belatacept serum concentration and 
the risk of acute rejection. A pooled analysis of 1425 intent-
to-treat patients (more intensive belatacept, n = 477; less 
intensive belatacept, n = 472; cyclosporine, n = 476) with 
a median follow-up of 2.4 years demonstrated that the 
incidences of serious adverse events were comparable in 
all three groups.48 The overall incidence of malignancies 
was slightly higher in the more intensive belatacept group 
(10% more intensive belatacept; 6% less intensive belata-
cept; 7% cyclosporine). A total of 15 cases of post-transplant 
lymphoproliferative disease, including eight cases involving 
the central nervous system, were reported. Of these post-
transplant lymphoproliferative disease cases, eight occurred 
on more intensive belatacept, five on less intensive belata-
cept, and two on cyclosporine. Six of eight central nervous 
system post-transplant lymphoproliferative disease cases 
were reported from the more intensive belatacept group 
and in two of eight from the less intensive belatacept group. 
EBV seronegative status was found to be the strongest risk 
factor. Although rates of polyomavirus infections were 
similar, herpes virus infections were higher in the belatacept 
groups. The incidence of death and serious infections was 
lowest in the less intensive belatacept group.
Vincenti et al recently published the five-year safety data 
of their initial Phase II study.49 Belatacept-treated patients 
did not have a higher frequency of serious infections or 
post-transplant lymphoproliferative disease compared with 
cyclosporine. Serious cardiac disorders occurred more fre-
quently with cyclosporine (2% for belatacept versus 12% 
for cyclosporine). Haidinger et al reported a renal transplant 
recipient on belatacept who developed fatal Pneumocystis 
jiroveci pneumonia four years post-transplant.50 Cyto-
megalovirus infection preceded the pneumonia, illustrating 
that excessive immunosuppression can result, even with a 
lymphocyte-specific regimen.
Conclusion
Belatacept, a selective T cell costimulation blocker, is a 
promising new therapy for maintenance immunosuppression 
among renal transplant recipients. It was originally antici-
pated that costimulation blockade would be successful in 
achieving immunologic allograft tolerance, but based upon 
current data this does not appear to be the case. Thus, the 
new paradigm revolves around the use of belatacept (among 
other molecules) for avoidance of calcineurin inhibitor neph-
rotoxicity and minimization of long-term cardiovascular and 
metabolic side effects. One main limitation of this medica-
tion is that administration requires an intravenous infusion. 
Although scheduled monthly infusions might improve 
compliance among a certain patient subset, eg, children, 
most mobile patients and those in remote locations could find 
themselves unable to adhere to such therapy. Furthermore, 
because the drug has a long half-life of 8–10 days, it might be 
difficult to dose patients battling with life-threatening infec-
tions appropriately. Owing to concerns about an increased 
post-transplant lymphoproliferative disease risk in EBV 
seronegative patients, current belatacept trial protocols have 
now been modified to enroll EBV seropositive patients only. 
Unfortunately, this exclusion will complicate the introduction 
of this drug for young patients, who might derive the maxi-
mum long-term benefit from non-nephrotoxic regimens. On a 
positive note, animal and human studies have demonstrated 
that the use of belatacept can lead to better renal function, 
along with a lower incidence of diabetes and cardiovascular 
risk factors. Although acute rejection seems to be more fre-
quent with belatacept, so far there are no data to suggest that Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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long-term renal allograft survival is shortened. Of course, the 
observed benefits in renal function as measured by calculated 
glomerular filtration rate will need to be confirmed using hard 
endpoints, including patient and allograft survival.
Disclosure
Karl L Womer is a recipient of salary support from Bristol-
Myers Squibb.
References
  1.  Suthanthiran M, Strom TB. Renal transplantation. N Engl J Med. 1994; 
331(6):365–376.
  2.  Organ Procurement and Transplant Network/Scientific Registry of 
Transplant Recipients Annual Report. 2009 Donation and transplanta-
tion trends. Available at: http://optn.transplant.hrsa.gov/latestData. 
Accessed 2010 Nov 10.
  3.  Cecka JM. The OPTN/UNOS Renal Transplant Registry. Clin Transpl. 
2005:1–16.
  4.  Samaniego M, Becker BN, Djamali A. Drug insight: Maintenance 
immunosuppression in kidney transplant recipients. Nat Clin Pract 
Nephrol. 2006;2(12):688–699.
  5.  Tantravahi J, Womer KL, Kaplan B. Why hasn’t eliminating acute rejec-
tion improved graft survival? Annu Rev Med. 2007;58:369–385.
  6.  Organ Procurement and Transplantation Network, based on OPTN data 
as of September 24, 2010. Available at: http://optn.transplant.hrsa.gov/
latestData. Accessed 2010 Nov 10.
  7.  Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. 
Strategies to improve long-term outcomes after renal transplantation. 
N Engl J Med. 2002;346(8):580–590.
  8.  Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, 
Chapman JR. The natural history of chronic allograft nephropathy.   
N Engl J Med. 2003;349(24):2326–2333.
  9.  Arend  SM,  Mallat  MJ, Westendorp  RJ,  van  der Woude  FJ, 
van Es LA. Patient survival after renal transplantation; more than   
25 years follow-up. Nephrol Dial Transplant. 1997;12(8):1672–1679.
  10.  Ojo AO. Cardiovascular complications after renal transplantation and 
their prevention. Transplantation. 2006;82(5):603–611.
  11.  Womer K, Rabb H. Immunosuppressive medications in kidney trans-
plantation. In: Feehally J, Johnson R, Floege J, editors. Comprehensive 
Clinical Nephrology. 4th ed. Mosby; 2010.
  12.  Glotz D, Charpentier B, Abramovicz D, et al. Thymoglobulin induc-
tion and sirolimus versus tacrolimus in kidney transplant recipients 
receiving mycophenolate mofetil and steroids. Transplantation. 
2010;89(12):1511–1517.
  13.  Jacquet A, Francois H, Frangie C, Ahmad L, Charpentier B, Durrbach A. 
Prevention of calcineurin inhibitor nephrotoxicity in renal transplanta-
tion. Transpl Immunol. 2008;20(1–2):29–31.
  14.  Buchler M, Caillard S, Barbier S, et al. Sirolimus versus cyclosporine in 
kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 
6-month course of steroids. Am J Transplant. 2007;7(11):2522–2531.
  15.  2008 Annual Report of the US Organ Procurement and Transplanta-
tion Network and the Scientific Registry of Transplant Recipients: 
Transplant Data 1998–2007. Available at: http://www.ustransplant.
org/annual_reports/current/506d_ki.htm. Accessed 2010 Nov 10.
  16.  Cooper JE, Wiseman AC. Novel immunosuppressive agents in kidney 
transplantation. Clin Nephrol. 2010;73(5):333–343.
  17.  Huang E, Womer K, Vincenti F. Biological agents in kidney trans-
plantation. In: Pereira B, Sayegh M, Blake P, editors. Chronic Kidney 
Disease, Dialysis, and Transplantation. 3rd ed. Philadelphia, PA: 
Elsevier Saunders; 2010.
  18.  Womer K, Rabb H. Immunologic principles in kidney transplantation. 
In: Feehally J, Johnson R, Floege J, editors. Comprehensive Clinical 
Nephrology. 4th ed. Mosby; 2010.
  19.  Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and 
autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev. 
2008;224:166–182.
  20.  Li XC, Rothstein DM, Sayegh MH. Costimulatory pathways in trans-
plantation: Challenges and new developments. Immunol Rev. 2009; 
229(1):271–293.
  21.  Linsley PS, Wallace PM, Johnson J, et al. Immunosuppression in vivo 
by a soluble form of the CTLA-4 T cell activation molecule. Science. 
1992;257(5071):792–795.
  22.  Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid 
arthritis by selective inhibition of T-cell activation with fusion protein 
CTLA4Ig. N Engl J Med. 2003;349(20):1907–1915.
  23.  Abrams JR, Kelley SL, Hayes E, et al. Blockade of T lymphocyte 
costimulation with cytotoxic T lymphocyte-associated antigen   
4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of 
psoriatic plaques, including the activation of keratinocytes, dendritic 
cells, and endothelial cells. J Exp Med. 2000;192(5):681–694.
  24.  Levisetti MG, Padrid PA, Szot GL, et al. Immunosuppressive effects 
of human CTLA4Ig in a non-human primate model of allogeneic pan-
creatic islet transplantation. J Immunol. 1997;159(11):5187–5191.
  25.  Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, Peach R. Human 
B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct 
kinetics to CD28 and CTLA-4 receptors. Immunity. 1994;1(9):793–801.
  26.  Larsen CP, Pearson TC, Adams AB, et al. Rational development of 
LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent 
immunosuppressive properties. Am J Transplant. 2005;5(3):443–453.
  27.  Latek R, Fleener C, Lamian V , et al. Assessment of belatacept-mediated 
costimulation blockade through evaluation of CD80/86-receptor 
  saturation. Transplantation. 2009;87(6):926–933.
  28.  Davis PM, Nadler S, Suchard SJ. Belatacept does not mediate 
complement-dependent cytotoxicity or antibody-dependent cellular 
cytotoxicity. Am J Transplant. 2008;8:619.
  29.  Sakaguchi S, Sakaguchi N, Shimizu J, et al. Immunologic tolerance 
maintained by CD25+ CD4+ regulatory T cells: Their common role 
in controlling autoimmunity, tumor immunity, and transplantation 
  tolerance. Immunol Rev. 2001;182:18–32.
  30.  Tang Q, Henriksen KJ, Boden EK, et al. Cutting edge: CD28 controls 
peripheral homeostasis of CD4+ CD25+ regulatory T cells. J Immunol. 
2003;171(7):3348–3352.
  31.  Rangel EB. Belatacept in clinical and experimental transplantation – 
progress and promise. Drugs Today (Barc). 2010;46(4):235–242.
  32.  Bluestone JA, Liu W, Yabu JM, et al. The effect of costimulatory and 
interleukin 2 receptor blockade on regulatory T cells in renal transplanta-
tion. Am J Transplant. 2008;8(10):2086–2096.
  33.  Vierboom MP, Ossevoort M, Sick EA, Haanstra K, Jonker M. Induction 
of allograft tolerance through costimulatory blockade: First selection 
of drugs in vitro. Transpl Immunol. 2003;11(2):215–222.
  34.  Kirk AD, Tadaki DK, Celniker A, et al. Induction therapy with mono-
clonal antibodies specific for CD80 and CD86 delays the onset of 
acute renal allograft rejection in non-human primates. Transplantation. 
2001;72(3):377–384.
  35.  Montgomery SP, Xu H, Tadaki DK, et al. Combination induction 
therapy with monoclonal antibodies specific for CD80, CD86, and 
CD154 in nonhuman primate renal transplantation. Transplantation. 
2002;74(10):1365–1369.
  36.  Emamaullee JA, Merani S, Larsen CP, Shapiro AM. Belatacept and 
basiliximab diminish human antiporcine xenoreactivity and synergize 
to inhibit alloimmunity. Transplantation. 2008;85(1):118–124.
  37.  Li C, Yang CW. The pathogenesis and treatment of chronic allograft 
nephropathy. Nat Rev Nephrol. 2009;5(9):513–519.
  38.  Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade 
with belatacept in renal transplantation. N Engl J Med. 2005;353(8): 
770–781.
  39.  Ferguson R, Vincenti F, Kaufman D, et al. Immunosuppression with 
belatacept-based, CNI-avoiding and steroid-avoiding regimens vs a tac-
rolimus-based, steroid-avoid regimen in kidney transplant patients: Results 
of a 1-year, randomized study. Transplantation. 2010;90 Suppl:156.Drug Design, Development and Therapy
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/drug-design-development-and-therapy-journal
Drug Design, Development and Therapy is an international, peer-
reviewed open-access journal that spans the spectrum of drug design 
and development through to clinical applications. Clinical outcomes, 
patient safety, and programs for the development and effective, safe, 
and sustained use of medicines are a feature of the journal, which 
has also been accepted for indexing on PubMed Central. The manu-
script management system is completely online and includes a very 
quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
382
Gupta and Womer
  40.  Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study 
of belatacept-based immunosuppression regimens versus cyclosporine 
in renal transplant recipients (BENEFIT study). Am J Transplant. 2008; 
10(3):535–546.
  41.  Larsen C, Grinyo JM, Charpentier B, et al. Belatacept vs cyclosporine 
in kidney transplant recipients: Two-year outcomes from the BENEFIT 
study. Transplantation. 2010;90 Suppl:158.
  42.  Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept 
versus cyclosporine in kidney transplants from extended criteria donors 
(BENEFIT-EXT study). Am J Transplant. 2010;10(3):547–557.
  43.  Durrbach A, Larsen C, Pestana JOM, et al. Belatacept vs cyclosporine 
in ECD kidney transplants: Two-year outcomes from the BENEFIT-EXT 
study. Transplantation. 2010;90 Suppl:157.
  44.  Rostaing L, Nainan G, Rial MC, et al. Switch from a CNI- to a 
belatacept-based immunosuppressive regimen in kidney transplant 
recipients is safe and results in better renal function: 12 month results 
from a Phase II study. Transplantation. 2010;90 Suppl:157.
  45.  Goring S, Eyawo O, Mills EJ, et al. A mixed treatment comparison of 
efficacy and cardiometabolic safety of belatacept, cyclospoorine and 
tacrolimus for immunosuppression therapy in adult renal transplant 
receipients. Transplantation. 2010;90 Suppl:75.
  46.  Vincenti F, Kirk AD. What’s next in the pipeline. Am J Transplant. 
2008;8(10):1972–1981.
47. Ashman N, Chapagain A, Dobbie H, et al. Belatacept as maintenance 
immunosuppression for postrenal transplant de novo drug-induced 
thrombotic microangiopathy. Am J Transplant. 2009;9(2): 
424–427.
  48.  Grinyo J, Charpentier B, Pestana J, et al. Safety profile of belatacept 
in kidney transplant recipients from a pooled analysis of phase II and 
phase III studies. Transplantation 2010;90 Suppl:156.
  49.  Vincenti F, Blancho G, Durrbach A, et al. Five-year safety and efficacy 
of belatacept in renal transplantation. J Am Soc Nephrol. 2010;21(9): 
1587–1596.
  50.  Haidinger M, Hecking M, Memarsadeghi M, et al. Late onset 
Pneumocystis pneumonia in renal transplantation after long-term 
immunosuppression with belatacept. Transpl Infect Dis. 2009;11(2): 
171–174.
  51.  Adams AB, Shirasugi N, Jones TR, et al. Development of a chimeric 
anti-CD40 monoclonal antibody that synergizes with LEA29Y to 
prolong islet allograft survival. J Immunol. 2005;174(1):542–550.
  52.  Cardona K, Korbutt GS, Milas Z, et al. Long-term survival of neo-
natal porcine islets in nonhuman primates by targeting costimulation 
  pathways. Nat Med. 2006;12(3):304–306.
  53.  Cardona K, Milas Z, Strobert E, et al. Engraftment of adult porcine 
islet xenografts in diabetic nonhuman primates through targeting of 
costimulation pathways. Am J Transplant. 2007;7(10):2260–2268.